Perlis Roy H, Ostacher Michael J, Patel Jayendra K, Marangell Lauren B, Zhang Hongwei, Wisniewski Stephen R, Ketter Terence A, Miklowitz David J, Otto Michael W, Gyulai Laszlo, Reilly-Harrington Noreen A, Nierenberg Andrew A, Sachs Gary S, Thase Michael E
Bipolar Clinical and Research Program, Massachusetts General Hospital, ACC 812, 15 Parkman Street, Boston, MA 02114, USA.
Am J Psychiatry. 2006 Feb;163(2):217-24. doi: 10.1176/appi.ajp.163.2.217.
Little is known about clinical features associated with the risk of recurrence in patients with bipolar disorder receiving treatment according to contemporary practice guidelines. The authors looked for the features associated with risk of recurrence.
The authors examined prospective data from a cohort of patients with bipolar disorder participating in the multicenter Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study for up to 24 months. For those who were symptomatic at study entry but subsequently achieved recovery, time to recurrence of mania, hypomania, mixed state, or a depressive episode was examined with Cox regression.
Of 1,469 participants symptomatic at study entry, 858 (58.4%) subsequently achieved recovery. During up to 2 years of follow-up, 416 (48.5%) of these individuals experienced recurrences, with more than twice as many developing depressive episodes (298, 34.7%) as those who developed manic, hypomanic, or mixed episodes (118, 13.8%). The time until 25% of the individuals experienced a depressive episode was 21.4 weeks and until 25% experienced a manic/hypomanic/mixed episode was 85.0 weeks. Residual depressive or manic symptoms at recovery and proportion of days depressed or anxious in the preceding year were significantly associated with shorter time to depressive recurrence. Residual manic symptoms at recovery and proportion of days of elevated mood in the preceding year were significantly associated with shorter time to manic, hypomanic, or mixed episode recurrence.
Recurrence was frequent and associated with the presence of residual mood symptoms at initial recovery. Targeting residual symptoms in maintenance treatment may represent an opportunity to reduce risk of recurrence.
对于按照当代实践指南接受治疗的双相情感障碍患者,与复发风险相关的临床特征知之甚少。作者探寻与复发风险相关的特征。
作者检查了参与多中心双相情感障碍系统治疗强化项目(STEP - BD)研究的双相情感障碍患者队列的前瞻性数据,随访时间长达24个月。对于那些在研究开始时有症状但随后康复的患者,采用Cox回归分析躁狂、轻躁狂、混合状态或抑郁发作的复发时间。
在1469名研究开始时有症状的参与者中,858名(58.4%)随后康复。在长达2年的随访期间,这些个体中有416名(48.5%)复发,其中出现抑郁发作的人数(298名,34.7%)是出现躁狂、轻躁狂或混合发作人数(118名,13.8%)的两倍多。25%的个体出现抑郁发作的时间为21.4周,出现躁狂/轻躁狂/混合发作的时间为85.0周。康复时残留的抑郁或躁狂症状以及前一年抑郁或焦虑的天数比例与抑郁复发时间缩短显著相关。康复时残留的躁狂症状以及前一年情绪高涨的天数比例与躁狂、轻躁狂或混合发作复发时间缩短显著相关。
复发很常见,且与初始康复时残留的情绪症状有关。在维持治疗中针对残留症状可能是降低复发风险的一个机会。